Stay well informed about transactions in the global life sciences industry
Register now:
Current Issue:
An overview of the topics in the current issue (March 2026):
- Transaction volume and value: The German life sciences sector proved robust overall in the M&A market in 2025. The number of transactions fell slightly, whilst the total value of deals rose at the same time.
- Strategic priority: Strategic buyers continued to dominate the deal landscape, focusing on expanding pipelines and capabilities.
- M&A focus: Buyers remained selective and concentrated on opportunities that complemented existing therapeutic areas, rather than expanding into unproven categories.
- Risk-mitigated M&A strategies: The risk profile played a decisive role in acquisition behaviour. Buyers preferred assets with tangible, near-to-market value over speculative pipeline assets.
- Dominant therapeutic areas: Oncology and immunology remained at the centre of deal activity, whilst neurology/CNS and cardiometabolic assets gained momentum.
Deal Capsule Life Sciences Newsletter - Archive
Here you will find all past issues of the newsletter, covering selected deals, developments in the M&A market, and the key issues shaping the sector’s transaction market.
Your contact
Christian Klingbeil
Partner, Deal Advisory, Valuation, Head of Life Sciences & Chemicals
KPMG AG Wirtschaftsprüfungsgesellschaft